Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109413 | PMC |
| http://dx.doi.org/10.1159/000502983 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complexity of social media in the era of generative AI.
Natl Sci Rev
January 2025
School of Cyber Science and Technology, University of Science and Technology of China, China.
The article presents a perspective on how the emerging generative AI technology can shape social media and the new challenges in studying social media in this generative.
View Article and Find Full Text PDFCurative immunotherapy-based strategies for non-metastatic non-small cell lung cancer.
Explor Target Antitumor Ther
December 2024
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, US.
The emergence of immunotherapy has ushered in a new era in the management of non-small cell lung cancer (NSCLC). Various immune check point inhibitors have demonstrated significant benefit in the management of locally advanced NSCLC that are treated with either surgery or concurrent chemoradiation. We provide a comprehensive and up-to-date review of data from key studies, discuss the challenging clinical issue regarding the timing and duration of immunotherapy in patients undergoing surgery, and highlight the unmet needs and future directions of immunotherapy in NSCLC.
View Article and Find Full Text PDFArtificial intelligence in lung cancer: current applications, future perspectives, and challenges.
Front Oncol
December 2024
Department of Respiratory and Critical Care Medicine, Center for Respiratory Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Artificial intelligence (AI) has significantly impacted various fields, including oncology. This comprehensive review examines the current applications and future prospects of AI in lung cancer research and treatment. We critically analyze the latest AI technologies and their applications across multiple domains, including genomics, transcriptomics, proteomics, metabolomics, immunomics, microbiomics, radiomics, and pathomics in lung cancer research.
View Article and Find Full Text PDFTrends and projections of type 2 diabetes mellitus in South Asia: a three-decade analysis and forecast through 2031 using global burden of disease study (1990 - 2021).
Expert Rev Endocrinol Metab
January 2025
Faculty of Medicine, University of Cyberjaya, Cyberjaya, Malaysia.
Background: The rapid rise of non-communicable diseases, particularly type 2 diabetes mellitus (T2DM), poses a significant global public health challenge, with South Asia experiencing an increasingly severe burden. This study aimed to analyse historical trends of T2DM across South Asia from 1990 to 2021 and forecast incidence through 2031.
Research Design And Methods: We carried out analysis based on the data from the 2021 Global burden of disease study.
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Stem Cell Res Ther
January 2025
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, 10F., Teaching & Research Building, Shuang-Ho Campus, No. 301, Yuantong Rd., Zhonghe Dist., Taipei, 235, Taiwan.
Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!